Journal of Critical Care
Volume 21, Issue 2 , Pages 173-178 , June 2006

Prophylactic low-molecular-weight heparin: Prescription practice in an intensive care unit

  • Patrick Tilleul

      Affiliations

    • APHP Pharmacie, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • ,
  • Gaëlle Tredan

      Affiliations

    • APHP Pharmacie, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • ,
  • Géraldine Austruy

      Affiliations

    • APHP Pharmacie, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • ,
  • Eric Maury

      Affiliations

    • APHP Service de Réanimation Médicale, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • INSERM U707, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • ,
  • Georges Offenstadt

      Affiliations

    • APHP Service de Réanimation Médicale, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • INSERM U707, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • Universite Pierre et Marie Curie, 75012 Paris, France
    • ,
  • Bertrand Guidet

      Affiliations

    • APHP Service de Réanimation Médicale, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • INSERM U707, Hôpital Saint Antoine, 75571 Paris cx 12, France
    • Universite Pierre et Marie Curie, 75012 Paris, France
    • Corresponding Author InformationCorresponding author. Intensive Care Unit, Hôpital Saint-Antoine, 75012 Paris, France. Tel.: +33 1 49 28 23 18; fax: +33 1 49 28 21 45.

References 

  1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism. Chest. 2004;126:338S–400S
  2. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbom C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study groupe. N Engl J Med. 1999;341:793–800
  3. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  4. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614–621
  5. Ravaud P, Durieux P, Fourcade A and the Comité Scientifique Thrombose AP-HP. Prophylaxie des thromboses veineuses post-opératoires: recommendations de l’Assistance publique des hôpitaux de Paris. Sang Thromb Vaisseaux. 1995;7:119–129
  6. Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest. 2003;124:357S–363S
  7. Goldhaber SZ, Turpie AGG. Prevention of venous thromboembolism among hospitalized medical patients. Circulation. 2005;111:e1–e3
  8. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995;274:335–337
  9. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–262
  10. Kakkar AK, Davidson BL, Haas SK. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost. 2004;2:221–227
  11. ANAES . L'audit clinique—bases méthodologiques de l’évaluation des pratiques professionnelles. Avril; 1999;
  12. Lacherade JC, Cook D, Heyland D, Chrusch C, Brochard L, Brun-Buisson C. Prevention of venous thromboembolism in critically ill medical patients. J Crit Care. 2003;18:228–237
  13. Etude des prescriptions des LMWH pour la prévention du risque thromboembolique veineux. AMPI. Régime, Service médical. Rapport d’étude, Novembre 1999.
  14. Lepaux DJ, Charpentier C, Pertek JP, Pinelli C, Delagoutte JP, Delorme N, et al. Assessment of deep vein thrombosis prophylaxis in surgical patients: a study conducted at Nancy Hospital University, France. Eur J Clin Pharmacol. 1998;54:671–676
  15. Bergmann JF. Prévention de la thrombose veineuse en milieu médical. Rev Prat. 1997;47:1399–1401
  16. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001;120:1964–1971
  17. Cestac P, Bagheri H, Lapeyre-Maestre M, Sie P, Fouladi A, Maupas E, et al. Utilisation and safety of low molecular weight heparins. Prospective observational study in medical inpatients. Drug Saf. 2003;26:197–207
  18. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224–228
  19. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696–700
  20. Levi D, Kupfter Y, Seneviratne C. Computerized order entry sets and intensive education improve the rate of prophylaxis for deep vein thrombophlebitis. Chest. 1998;114:280

PII: S0883-9441(06)00038-4

doi: 10.1016/j.jcrc.2005.12.013

Journal of Critical Care
Volume 21, Issue 2 , Pages 173-178 , June 2006

Article Tools